用T细胞参与治疗的细胞释放综合征风险模型
Pénélope Lafeuille1, William A Blumentals2, Claire Brulle-Wohlhueter3
1Medidata Solutions, New York, New York, USA.
Cytotherapy
|August 23, 2025
概括
一个新的模型预测了在接受T细胞参与治疗 (TCE) 的患者中出现严重的细胞因子释放综合征 (CRS) 的风险. 这种风险分层可以改善患者的选择和监测,以获得更好的治疗结果.
科学领域:
- 癌症学
- 免疫疗法
- 临床试验分析
背景情况:
- 细胞因子释放综合征 (CRS) 是T细胞参与 (TCE) 疗法,包括CAR- T细胞和双特异性抗体的一个显著不良事件.
- 准确预测CRS风险对于优化患者管理和治疗安全至关重要.
研究的目的:
- 在TCE双特异抗体治疗前开发和验证一种预测模型,用于识别患有≥2级细胞因子释放综合征 (CRS) 的高风险患者.
- 专注于血液恶性瘤 (急性淋巴细胞白血病,非霍奇金淋巴瘤) 和固体瘤的患者.
主要方法:
- 使用了涉及非CAR-T TCE疗法的已完成临床试验 (2014 - 2019) 的数据集.
- 从文献和初步分析中确定了风险因素,测量了治疗前的特征.
- 训练后勤回归和基于树的模型,使用100次代的平均AUROC评估性能.
主要成果:
- 最好的预测模型的平均AUROC为0. 69 (95% CI:0. 66- 0. 72).
- 与最低风险四分位数相比,最高风险四分位数患者的CRS发生率增加了5. 9倍.
- 高CRS风险的关键预测因素包括ALL类型的疾病,较高的TCE剂量,先前感染和血清肌水平升高.
结论:
- 经过验证的风险模型可以有效地根据患者患上≥2级CRS的可能性进行分层.
- 风险分层可以指导患者选择TCE治疗,并为个性化预治疗和监测策略提供信息.
- 这种方法旨在提高免疫瘤治疗的疗效和患者安全.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.5K
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.5K
相关概念视频
Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
T Cell Activation and Clonal Selection
4.5K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
4.5K
Cytotoxic T Cells-mediated Immune Response
1.9K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.9K
T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
